Italia markets close in 3 hours 8 minutes

FTSE MIB
34.534,60
-290,41(-0,83%)
Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
38.946,93
-122,75(-0,31%)
Petrolio
78,31
-1,49(-1,87%)
Bitcoin EUR
65.590,85
+3.851,09(+6,24%)

NVCR Dec 2025 7.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

10,00

0,00

(0,00%)

In data: 01:48PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in